News
Centene Corporation (NYSE:CNC) is one of the Best Beaten Down Stocks to Buy Now. Bank of America downgraded the company’s ...
Centene (CNC) stock and HCA Healthcare (HCA) stock are downgraded at Bank of America based on risks from Trump’s One Big Beautiful Bill Act. Read more here.
10h
TipRanks on MSNOklo, Southwest, ASML, Axon, Centene: Trending by AnalystsAnalysts are intrested in these 5 stocks: ( ($OKLO) ), ( ($LUV) ), ( ($ASML) ), ( ($AXON) ) and ( ($CNC) ). Here is a ...
3d
Fintel on MSNB of A Securities Downgrades Centene (CNC)Fintel reports that on July 16, 2025, B of A Securities downgraded their outlook for Centene (NYSE:CNC) from Neutral to ...
The Clayton-based health giant is likely to face increased challenges as federal government tightens Medicaid eligibility and ...
Investing.com - UBS downgraded Centene (NYSE:CNC) stock rating from Buy to Neutral on Wednesday, slashing its price target to $45.00 from $80.00 following the healthcare company’s withdrawal of ...
Centene (NYSE:CNC) stock was downgraded by Argus citing an uncertain outlook for its certain state-level operations and its Medicare Advantage business. Read more here.
Shares of health coverage company Centene (NYSE:CNC) fell 39.4% in the afternoon session after the company unexpectedly withdrew its full-year 2025 financial guidance, citing significantly higher ...
J.P. Morgan analyst John Stansel downgraded Centene's stock to neutral from overweight, as it remains unclear how the company will be able to correct its healthcare pricing in 2026, given the ...
UBS downgraded Centene’s stock from Buy to Neutral, citing the company’s withdrawal of guidance and concerns over earnings. The firm projects a significant decline in Centene’s earnings per ...
Argus downgraded Centene (CNC) to Hold from Buy. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions ...
Investing.com - UBS downgraded Centene (NYSE: CNC) stock rating from Buy to Neutral on Wednesday, slashing its price target to $45.00 from $80.00 following the healthcare company’s withdrawal of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results